Introduction {#vox12367-sec-0005}
============

First established in France and Japan in 1993 as a response to the vulnerability of the blood supply after the emergence of HIV [1](#vox12367-bib-0001){ref-type="ref"}, [2](#vox12367-bib-0002){ref-type="ref"}, haemovigilance systems aim to improve the safety of the blood supply through systematic surveillance of transfusion‐related adverse events. Such systems generate recommendations so as to encourage safety throughout the entire process, from blood donation through monitoring of recipients. Several directives from the European Union relate to the regulation, monitoring and safety of blood products, with the haemovigilance component helping to direct member nations' reporting of serious transfusion‐related adverse reactions and events [3](#vox12367-bib-0003){ref-type="ref"}. Therefore, haemovigilance systems are widespread in European nations, with prime examples being the United Kingdom with its voluntary Serious Hazards of Transfusion reporting system (99·5% participation in 2013) [4](#vox12367-bib-0004){ref-type="ref"}, and the Netherlands with its Transfusion and Transplantation Reactions in Patients haemovigilance programme (98% participation in 2013) [5](#vox12367-bib-0005){ref-type="ref"}.

The USA opened its first nationwide haemovigilance system in 2010 as a voluntary module of the National Healthcare Safety Network [6](#vox12367-bib-0006){ref-type="ref"}. Results from this new system are now available and can be compared with existing haemovigilance programmes. As more nations begin to implement haemovigilance programmes, an assessment of the abilities of national systems to report reactions and a comparative review of event rates can be informative.

Methods {#vox12367-sec-0006}
=======

Haemovigilance data on transfusion‐related adverse reactions and transfusion‐transmitted infections were available from the national haemovigilance systems in each of the following countries: Australia [7](#vox12367-bib-0007){ref-type="ref"}, Canada [8](#vox12367-bib-0008){ref-type="ref"}, Denmark [9](#vox12367-bib-0009){ref-type="ref"}, Finland [10](#vox12367-bib-0010){ref-type="ref"}, France [11](#vox12367-bib-0011){ref-type="ref"}, Germany [12](#vox12367-bib-0012){ref-type="ref"}, Ireland [13](#vox12367-bib-0013){ref-type="ref"}, Japan [14](#vox12367-bib-0014){ref-type="ref"}, [15](#vox12367-bib-0015){ref-type="ref"}, [16](#vox12367-bib-0016){ref-type="ref"}, the Netherlands [5](#vox12367-bib-0005){ref-type="ref"}, New Zealand [17](#vox12367-bib-0017){ref-type="ref"}, Norway [18](#vox12367-bib-0018){ref-type="ref"}, Portugal [19](#vox12367-bib-0019){ref-type="ref"}, [20](#vox12367-bib-0020){ref-type="ref"}, Spain [21](#vox12367-bib-0021){ref-type="ref"}, Sweden [22](#vox12367-bib-0022){ref-type="ref"}, Switzerland [23](#vox12367-bib-0023){ref-type="ref"}, United Kingdom[4](#vox12367-bib-0004){ref-type="ref"} and the USA [6](#vox12367-bib-0006){ref-type="ref"}. Data regarding adverse events after RBC transfusion were collected: allergic reactions, anaphylactic reactions, febrile non‐haemolytic transfusion reactions (FNHTR), acute and delayed haemolytic transfusion reactions, hypotensive reactions, transfusion‐related acute lung injury (TRALI), transfusion‐associated dyspnoea, transfusion‐associated circulatory overload (TACO), delayed serologic transfusion reactions, post‐transfusion purpura and transfusion‐transmitted bacterial sepsis. Some countries reported additional categories and these were included as well (acute transfusion‐related pain, haemosiderosis). For each country, data from the most recently available report were utilized.

Risks of transfusion‐transmitted viruses were available for agents with mandated testing. Reporting methods differ by country, although in the USA, data regarding residual risk of viral transmission were derived from donor testing since long‐term follow‐up of recipients is not feasible [24](#vox12367-bib-0024){ref-type="ref"}. Because it is theoretically possible that a donor could have newly acquired a virus but is sero‐negative at the time of the blood donation, seroconversion rates during this infectious window period are used to predict the residual risk of viral infection [24](#vox12367-bib-0024){ref-type="ref"}.

Statistical analyses {#vox12367-sec-0007}
--------------------

Rates of non‐infectious adverse events were calculated for each country using the number of events (numerator) and the number of RBC units administered (denominator). Rates were reported for each country as events per 100 000 RBC units for non‐infectious adverse events and events per million RBC units for infectious adverse events. Canada and Spain were exceptions; adverse events were recorded for components combined (RBCs, platelets, plasma). In the USA, TACO was the only event in which reporting was performed for components combined (RBCs, platelets, plasma). In secondary analyses, adverse event rates from active surveillance in the USA were compared with the rates generated from the passive haemovigilance programme; in these instances, the rates were given using several denominators (per patient, per unit and per transfusion‐related hospital stay).

Following current recommendations for summarizing rates [25](#vox12367-bib-0025){ref-type="ref"}, random‐effects Poisson regression models were generated to pool rates of transfusion‐related adverse events with 95% confidence intervals. That is, the numbers of events were fit to a Poisson distribution with the number of RBC units included as an offset. Countries that reported zero events were included and, in such instances, a one‐sided exact Poisson 97·5% confidence interval was used for the country‐specific rate. Heterogeneity was assessed using a gamma density function (shape parameter = 2, scale = 0·5) for the variance of the random intercept (between‐country variance) in the Poisson model. This Rate Index of Heterogeneity (RIH) is unit‐independent, encompasses a range from 0% to 100% heterogeneity and is directly derived from the underlying random‐effects Poisson model for assessment of rates. Analyses were conducted using Stata/MP 13·1 (College Station, Texas, USA).

Results {#vox12367-sec-0008}
=======

Allergic reactions after RBC transfusion occurred in 11 patients per 100 000 RBC units administered (95% CI: 6·55/100 000 to 18·08/100 000) with a RIH of 58·5% (Fig. [1](#vox12367-fig-0001){ref-type="fig"}). The rate of allergic reactions in the USA was significantly greater (53·61/100 000; 95% CI: 49·59/100 000--57·87/100 000) than the pooled rate of the other developed countries combined (9·7/100 000; 95% CI: 5·93/100 000--15·85/100 000). Some countries reported anaphylactic reactions separately and these occurred at a lower rate of 0·9 per 100 000 RBC units (RIH = 17·1%). In the United Kingdom, acute transfusion reactions were defined as instances of anaphylaxis or severe allergic reactions, severe febrile reactions, severe hypotensive reactions and severe mixed reactions; these occurred at a rate of nine patients per 100 000 RBC units.

![Rates of allergic reactions in haemovigilance reports, by Country.](VOX-110-266-g001){#vox12367-fig-0001}

There was variability in the rates of FNHTR across countries (RIH = 94·0%). Overall, the rate was 26 patients per 100 000 RBC units, although the Netherlands, New Zealand and the USA recorded rates in excess of 100 patients per 100 000 RBC units, or approximately one in one‐thousand units (Fig. [2](#vox12367-fig-0002){ref-type="fig"}). The rate of FNHTR in the USA was significantly greater (106·32/100 000; 95% CI: 100·63/100 000--112·25/100 000) than the pooled rate of the other developed countries combined (22·85/100 000; 95% CI: 9·74/100 000--53·63/100 000). Hypotensive reactions after RBC transfusion occurred less frequently, in 2 patients per 100 000 RBC units (RIH = 34·3%). In Spain, hypotensive reactions were combined with FNHTR, yielding a rate of 48 patients in 100 000 RBC units.

![Rates of acute transfusion reactions in haemovigilance reports, by Country.](VOX-110-266-g002){#vox12367-fig-0002}

Acute transfusion‐related pain was reported separately in the Swedish haemovigilance system, occurring in one patient per 100 000 RBC units (Fig. [2](#vox12367-fig-0002){ref-type="fig"}).

Rates of acute and delayed haemolytic transfusion reactions are shown in Fig. [3](#vox12367-fig-0003){ref-type="fig"}. Acute haemolytic transfusion reactions occurred in 1 patient per 100 000 RBC units administered (RIH = 8·3%), while a delayed haemolytic transfusion reaction occurred in approximately two patients per 100 000 RBC units (RIH = 37·6%). In Germany, Spain and the United Kingdom, both acute and delayed haemolytic transfusion reactions were combined, yielding a pooled rate of 1·4/100 000 units (RIH = 57·0%). Both Ireland and the USA tended to have delayed haemolytic transfusion reactions at a greater frequency than other countries, although the confidence intervals for Ireland were wide indicating fewer RBC units due to a smaller population. The rate of delayed haemolytic transfusion reactions in the USA was significantly greater (6·94/100 000; 95% CI: 5·54/100 000--8·58/100 000) than the pooled rate of the other developed countries combined (1·6/100 000; 95% CI: 0·9/100 000--2·8/100 000).

![Rates of haemolytic reactions in haemovigilance reports, by Country.](VOX-110-266-g003){#vox12367-fig-0003}

Respiratory reactions to RBC transfusion are shown in Fig. [4](#vox12367-fig-0004){ref-type="fig"}. Transfusion‐associated dyspnoea was reported in two patients per 100 000 RBC units (RIH = 77·4%). New Zealand was an outlier in this category. TRALI associated with RBC units was quite low (Fig. [4](#vox12367-fig-0004){ref-type="fig"}), at a pooled rate of 0·35 per 100 000 RBC units (RIH = 73·2%).

![Rates of respiratory transfusion reactions in haemovigilance reports, by Country.](VOX-110-266-g004){#vox12367-fig-0004}

TACO occurred in approximately three patients for each 100 000 RBC units transfused, although there was some variation in rates across countries (Fig. [5](#vox12367-fig-0005){ref-type="fig"}; RIH = 76·9%). Haemosiderosis was reported separately in France and Spain and occurred at a rate of 0·3 for every 100 000 units transfused (RIH = 99·6%).

![Rates of circulatory overload in haemovigilance reports, by Country.](VOX-110-266-g005){#vox12367-fig-0005}

The results for delayed serologic transfusion reactions are given in Fig. [6](#vox12367-fig-0006){ref-type="fig"}, showing heterogeneity across countries (RIH = 91·5%; rate = 24·6/100 000 units), with elevated rates in the Netherlands and Switzerland. Post‐transfusion purpura occurred rarely, at a rate of 0·08 per 100 000 RBC units administered (Fig. [6](#vox12367-fig-0006){ref-type="fig"}; RIH = 0%). Other transfusion‐related reactions, as shown in Fig. [6](#vox12367-fig-0006){ref-type="fig"}, varied by country and were not described in great detail in the country‐specific annual reports.

![Rates of other transfusion reactions in haemovigilance reports, by Country.](VOX-110-266-g006){#vox12367-fig-0006}

Documented cases of transfusion‐transmitted bacterial sepsis occurred rarely, approximately once in every million RBC units administered (Fig. [7](#vox12367-fig-0007){ref-type="fig"}; RIH = 57·8%).

![Rates of transfusion‐transmitted bacterial sepsis in haemovigilance reports, by Country.](VOX-110-266-g007){#vox12367-fig-0007}

Table [1](#vox12367-tbl-0001){ref-type="table"} displays the estimate residual risk of viral transmission due to RBC transfusion. Rates were very low. HIV and hepatitis B and C viruses were most often monitored through haemovigilance, while data regarding other viruses (cytomegalovirus, Epstein--Barr, etc.) were available from only a few countries.

###### 

Risk of transfusion‐transmitted viruses in haemovigilance reports, by Country

  Virus                          Country           Years                Rate
  ------------------------------ ----------------- -------------------- ------------------
  Cytomegalovirus                France            2009                 1 in 1·5 million
  The Netherlands                2012              \<1 in 620 000       
  Norway                         2004--2010        1 in 1·4 million     
  Epstein--Barr Virus            The Netherlands   2012                 \<1 in 620 000
  Hepatitis A Virus              France            2009                 \<1 in 3 million
  The Netherlands                2012              \<1 in 620 000       
  Norway                         2004--2010        1 in 1·4 million     
  Hepatitis B Virus              Australia         2012--2013           1 in 720 000
  Canada                         2006--2009        1 in 1·7 million     
  Denmark                        2009              1 in 270 000         
  Finland                        2007              \<1 in 450 000       
  France                         2009              \<1 in 3 million     
  Germany                        2010              1 in 6·1 million     
  Ireland                        2010--2011        \<1 in 190 000       
  Japan                          2012              1 in 880 000         
  The Netherlands                2012              \<1 in 620 000       
  New Zealand                    2013              1 in 68 000          
  Spain                          2013              1 in 1·9 million     
  Switzerland                    2013              1 in 400 000         
  UK                             2013              1 in 2·8 million     
  USA                            2006--2008        1 in 300 000         
  Hepatitis C Virus              Australia         2012--2013           \<1 in 1 million
  Canada                         2006--2009        1 in 6·7 million     
  Denmark                        2009              \<1 in 540 000       
  Finland                        2007              \<1 in 450 000       
  France                         2009              \<1 in 3 million     
  Germany                        2010              \<1 in 6·1 million   
  Ireland                        2010--2011        \<1 in 190 000       
  The Netherlands                2012              \<1 in 620 000       
  Sweden                         2013              \<1 in 460 000       
  Switzerland                    2013              1 in 6·7 million     
  UK                             2013              \<1 in 2·8 million   
  USA                            2007--2008        1 in 1·1 million     
  Hepatitis E Virus              France            2009                 \<1 in 3 million
  Japan                          2012              1 in 1·3 million     
  UK                             2013              1 in 2·8 million     
  Human Immunodeficiency Virus   Australia         2012--2013           \<1 in 1 million
  Canada                         2006--2009        1 in 8 million       
  Denmark                        2009              \<1 in 540 000       
  Finland                        2007              \<1 in 450 000       
  France                         2009              \<1 in 3 million     
  Germany                        2010              1 in 6·1 million     
  Ireland                        2010--2011        \<1 in 190 000       
  The Netherlands                2012              \<1 in 620 000       
  New Zealand                    2013              \<1 in 140 000       
  Switzerland                    2013              1 in 4·1 million     
  UK                             2013              \<1 in 2·8 million   
  USA                            2007--2008        1 in 1·5 million     
  Human T‐Lymphotropic Virus     Australia         2012--2013           \<1 in 1 million
  The Netherlands                2012              \<1 in 620 000       
  USA                            2000--2001        1 in 2·1 million     
  Parvovirus B19                 France            2009                 1 in 3 million
  The Netherlands                2012              \<1 in 620 000       
  Norway                         2004--2010        1 in 1·4 million     
  Varicella Zoster Virus         Norway            2004--2010           1 in 1·4 million
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Rates of adverse reactions in the USA, as generated through haemovigilance, were compared to documented rates obtained through active surveillance. Published frequency rates of TACO are shown in Table [2](#vox12367-tbl-0002){ref-type="table"} [26](#vox12367-bib-0026){ref-type="ref"}, [27](#vox12367-bib-0027){ref-type="ref"}, [28](#vox12367-bib-0028){ref-type="ref"}, [29](#vox12367-bib-0029){ref-type="ref"}, [30](#vox12367-bib-0030){ref-type="ref"}, [31](#vox12367-bib-0031){ref-type="ref"}, [32](#vox12367-bib-0032){ref-type="ref"}. When units were used as the denominator, the pooled rate of TACO was 368 per 100 000 units or one in every 271 units from active surveillance. This compares with one in 10942 units from passive surveillance through the haemovigilance programme in the USA.

###### 

Incidence of transfusion‐associated circulatory overload in the United States

  Author, year                                                  Source                                                      Type of study              Incidence            Incidence           Components   Year
  ------------------------------------------------------------- ----------------------------------------------------------- -------------------------- -------------------- ------------------- ------------ ----------------------
  Frequency per patient                                                                                                                                                                                      
  Popovsky [26](#vox12367-bib-0026){ref-type="ref"}, 1996       5 Massachusetts hospitals, total hip or knee replacements   Retrospective cohort       1·0% of patients     1 in 95 patients    All          1992--1993
  Bierbaum [27](#vox12367-bib-0027){ref-type="ref"}, 1999       235 hospitals, total hip or knee arthroplasty               Prospective cohort         8·0% of patients     1 in 12 patients    All          1996--1997
  Rana [28](#vox12367-bib-0028){ref-type="ref"}, 2006           Mayo Clinic, intensive care units                           Prospective cohort         1·85% of patients    1 in 54 patients    All          2003
  Li [29](#vox12367-bib-0029){ref-type="ref"}, 2011             Mayo Clinic, medical intensive care unit                    Prospective cohort         5·7% of patients     1 in 18 patients    All          2 years, before 2007
  Andrzejewski [30](#vox12367-bib-0030){ref-type="ref"}, 2012   Hospital in Massachusetts, all ages                         Retrospective cohort       0·6% of patients     1 in 166 patients   RBCs         2005--2008
  Clifford [31](#vox12367-bib-0031){ref-type="ref"}, 2015       Mayo Clinic, adults, non‐cardiac surgery                    Retrospective cohort       5·5% of patients     1 in 18 patients    All          2004
  3·0% of patients                                              1 in 33 patients                                            All                        2011                                                  
  Frequency per unit:                                                                                                                                                                                        
  Rana [28](#vox12367-bib-0028){ref-type="ref"}, 2006           Mayo Clinic, intensive care units                           Prospective cohort         281/100 000 units    1 in 356 units      All          2003
  Andrzejewski [30](#vox12367-bib-0030){ref-type="ref"}, 2012   Hospital in Massachusetts, all ages                         Retrospective cohort       189/100 000 units    1 in 530 units      RBCs         2005--2008
  Harvey [6](#vox12367-bib-0006){ref-type="ref"}, 2014          National Healthcare Safety Network, 77 facilities           Voluntary haemovigilance   9/100 000 units      1 in 10942 units    All          2010--2012
  Clifford [31](#vox12367-bib-0031){ref-type="ref"}, 2015       Mayo Clinic, adults, non‐cardiac surgery                    Retrospective cohort       4000/100 000 units   1 in 25 units       RBCs         2004
  1087/100 000 units                                            1 in 92 units                                               RBCs                       2011                                                  
  Frequency per hospital stay                                                                                                                                                                                
  Menis [32](#vox12367-bib-0032){ref-type="ref"}, 2014          Medicare administrative database                            Retrospective              0·06% of stays       1 in 1602 stays     All          2011
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In general, rates of FNHTR were lower in leucoreduced versus non‐leucoreduced products within the same population (Table [3](#vox12367-tbl-0003){ref-type="table"}) [33](#vox12367-bib-0033){ref-type="ref"}, [34](#vox12367-bib-0034){ref-type="ref"}, [35](#vox12367-bib-0035){ref-type="ref"}, [36](#vox12367-bib-0036){ref-type="ref"}, [37](#vox12367-bib-0037){ref-type="ref"}, [38](#vox12367-bib-0038){ref-type="ref"}, [39](#vox12367-bib-0039){ref-type="ref"}, [40](#vox12367-bib-0040){ref-type="ref"}, [41](#vox12367-bib-0041){ref-type="ref"}, [42](#vox12367-bib-0042){ref-type="ref"}, [43](#vox12367-bib-0043){ref-type="ref"}, [44](#vox12367-bib-0044){ref-type="ref"}. With prospective surveillance, the pooled rate of FNHTR was 1191/100 000 units or one in every 84 units; this compares with one case in 3885 RBC units from haemovigilance. The rates tended to be greater in children than adults; one in 20 children who received a transfusion developed FNHTR (all component types combined). FNHTR rates also appeared higher in patients with cancer.

###### 

Incidence of febrile non‐haemolytic transfusion reaction in the United States

  Author, year                                                  Source                                                        Type of study                     Incidence                       Incidence                    Components                          Year
  ------------------------------------------------------------- ------------------------------------------------------------- --------------------------------- ------------------------------- ---------------------------- ----------------------------------- -------------
  Frequency per patient                                                                                                                                                                                                                                          
  Paglino [33](#vox12367-bib-0033){ref-type="ref"}, 2004        Yale‐New Haven Hospital, Connecticut, all ages                Retrospective cohort              1·33% of patients               1 in 75 patients             25% leucoreduced RBCs               1995--1998
  0·79% of patients                                             1 in 127 patients                                             99% leucoreduced RBCs             2000--2002                                                                                       
  Sanders [34](#vox12367-bib-0034){ref-type="ref"}, 2005        St. Jude Children\'s Research Hospital                        Retrospective cohort              4·94% of children               1 in 20 children             All                                 2002
  Kennedy [35](#vox12367-bib-0035){ref-type="ref"}, 2008        Wake Forest University, Comprehensive Cancer Center           Prospective active surveillance   8·70% of patients               1 in 11 patients             RBCs and PLTs, leucoreduced         1993--1997
  Frequency per unit                                                                                                                                                                                                                                             
  Menitove [36](#vox12367-bib-0036){ref-type="ref"}, 1982       33 Hospitals in South‐eastern Wisconsin, all ages             Retrospective cohort              478/100 000 units               1 in 209 units               RBCs and whole blood                1980
  Dzieczkowski [37](#vox12367-bib-0037){ref-type="ref"}, 1995   Dana‐Farber Cancer Institute, Boston, Massachusetts           Prospective cohort                2147/100 000 units              1 in 47 units                RBCs, leucoreduced after storage    1993
  Federowicz [38](#vox12367-bib-0038){ref-type="ref"}, 1996     Dana‐Farber Cancer Institute, Boston, Massachusetts           Prospective cohort                1109/100 000 units              1 in 90 units                RBCs, leucoreduced before storage   Before 1995
  Uhlman [39](#vox12367-bib-0039){ref-type="ref"}, 2001         Barnes‐Jewish Hospital, St. Louis, Missouri                   Retrospective cohort              124/100 000 units               1 in 809 units               Non‐leucoreduced RBCs               1999
  81/100 000 units                                              1 in 1238 units                                               Leucoreduced RBCs                 2000                                                                                             
  Domen [40](#vox12367-bib-0040){ref-type="ref"}, 2003          Cleveland Clinic, Ohio, all ages                              Retrospective cohort              30/100 000 units                1 in 3293 units              RBCs                                1993--2001
  Paglino [33](#vox12367-bib-0033){ref-type="ref"}, 2004        Yale‐New Haven Hospital, Connecticut, all ages                Retrospective cohort              340/100 000 units               1 in 294 units               25% leucoreduced RBCs               1995--1998
  180/100 000 units                                             1 in 556 units                                                99% leucoreduced RBCs             2000--2002                                                                                       
  King [41](#vox12367-bib-0041){ref-type="ref"}, 2004           The Johns Hopkins Hospital, all ages                          Retrospective cohort              369/100 000 units               1 in 271 units               4% leucoreduced RBCs                1994
  186/100 000 units                                             1 in 538 units                                                99·5% leucoreduced RBCs           2001                                                                                             
  Ezidiegwu [42](#vox12367-bib-0042){ref-type="ref"}, 2004      State University of New York, Syracuse, adults, nonsurgical   Retrospective cohort              162/100 000 units               1 in 619 units               RBCs                                1998--2000
  79/100 000 units                                              1 in 1259 units                                               Leucoreduced RBCs                 2001--2002                                                                                       
  Sanders [34](#vox12367-bib-0034){ref-type="ref"}, 2005        St. Jude Children\'s Research Hospital                        Retrospective cohort              360/100 000 units in children   1 in 278 units in children   RBCs                                2002
  Kennedy [35](#vox12367-bib-0035){ref-type="ref"}, 2008        Wake Forest University, Comprehensive Cancer Center           Prospective active surveillance   639/100 000 units               1 in 156 units               RBCs and PLTs, leucoreduced         1993--1997
  Harvey [6](#vox12367-bib-0006){ref-type="ref"}, 2014          National Healthcare Safety Network, 77 facilities             Voluntary haemovigilance          106/100 000 units               1 in 941 units               RBCs                                2010--2012
  Oakley [43](#vox12367-bib-0043){ref-type="ref"}, 2015         Vanderbilt University Medical Center, all ages                Retrospective cohort              184/100 000 units in children   1 in 545 units in children   Leucoreduced RBCs                   2011--2013
  36/100 000 units in adults                                    1 in 2775 units in adults                                     Leucoreduced RBCs                 2011--2013                                                                                       
  Frequency per hospital stay                                                                                                                                                                                                                                    
  Menis [44](#vox12367-bib-0044){ref-type="ref"}, 2015          Medicare administrative database                              Retrospective                     0·07% of stays                  1 in 1419 stays              RBCs                                2011--2012
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Discussion {#vox12367-sec-0009}
==========

Haemovigilance systems in developed nations report low rates of adverse events after RBC transfusion. For anaphylaxis, hypotension and purpura, the rates were quite consistent across countries. Rates of some reactions, however, were notably elevated in particular countries. Rates of allergic reactions were higher in the USA and New Zealand; rates of FNHTR were elevated in the USA, the Netherlands and New Zealand; and TACO was more commonly reported in Canada, France, Ireland, the Netherlands and the USA. New Zealand reported a greater rate of transfusion‐associated dyspnoea in 2013. However, in a recent report, more than half of the dyspnoea cases were reclassified when additional information was retrieved (many being reclassified as TACO) [45](#vox12367-bib-0045){ref-type="ref"}.

Overall, TACO occurred at a rate of three cases per 100 000 units when pooled from haemovigilance reports, with the incidence of TACO in the USA alone being one in 10942 units. However, based on active surveillance studies from the USA, 0·6% to 8% of patients receiving RBC transfusions develop TACO. This disparity between active and passive surveillance rates may stem from insufficient reporting of reactions to haemovigilance systems. For example, researchers from the Mayo Clinic noted that there were 176 cases of TACO in their investigation but only three were in the transfusion database that housed adverse reactions -- and even then, these three cases were not labelled as TACO [31](#vox12367-bib-0031){ref-type="ref"}.

Given the more comprehensive monitoring of fever after RBC transfusion, the variability of rates of FNHTR across countries may be a reflection of dissimilarities in patient populations, differential use of pretransfusion antipyretic medications or the preparation of RBC units. Of note, the USA has not adopted universal leucoreduction (70·5% RBC units leucoreduced in 2011)[46](#vox12367-bib-0046){ref-type="ref"} and FNHTR has been reported more frequently in patients receiving non‐leucoreduced products [33](#vox12367-bib-0033){ref-type="ref"}, [39](#vox12367-bib-0039){ref-type="ref"}, [41](#vox12367-bib-0041){ref-type="ref"}, [42](#vox12367-bib-0042){ref-type="ref"}, [47](#vox12367-bib-0047){ref-type="ref"}. FNHTR rates in the USA are higher than the pooled FNHTR rates in other developed countries and the use of non‐leucoreduced products could partially account for these findings.

The variability in rates of allergic reactions across nations may stem from differences in case definitions. In Australia, for example, a severe allergic reaction would be recorded if rash, allergic dyspnoea, angioedema, generalized pruritis or uticaria occurred within 24 h of the transfusion [7](#vox12367-bib-0007){ref-type="ref"}. In the USA, a severe allergic reaction would be recorded if two or more symptoms (conjunctival oedema; oedema of lips, tongue and uvula; erythema and oedema of the periorbital area; generalized flushing; hypotension; localized angioedema; maculopapular rash; pruritus; respiratory distress or bronchospasm; urticaria) occurred during or within 4 h of the cessation of transfusion [48](#vox12367-bib-0048){ref-type="ref"}. Moreover, in some countries such as New Zealand, both non‐severe and severe allergic reactions are reported[17](#vox12367-bib-0017){ref-type="ref"} (perhaps reflecting their higher rates as shown in Fig. [1](#vox12367-fig-0001){ref-type="fig"}) while in the USA, reporting of non‐severe allergic reactions is not required [48](#vox12367-bib-0048){ref-type="ref"}. Other reasons for differences in rates may be variations in hospital‐specific reporting practices and the mandatory/voluntary nature of the reporting.

For events such as delayed serologic transfusion reaction and delayed haemolytic transfusion reaction, the definition hinges on laboratory testing and not symptoms. Rate differences may be a reflection of the resources afforded for testing of alloantibodies and the feasibility of longitudinal observation. Information regarding follow‐up procedures or standardization of procedures would enhance the interpretability of rates. Alternatively, haemovigilance programmes may reconsider the usefulness of expending resources to capture such data when the likelihood of consistent, meaningful information is low. Perhaps periodic systematic testing in high users of transfusion would be more appropriate such as in patients with sickle‐cell disease or cancer, or in participants of cardiovascular disease registries.

Results from this investigation indicate that the residual risks from currently tested infectious agents are very low and, in many instances, could be considered negligible. However, it is the potential risks from other infectious agents (not yet tested) which are more pertinent at this time. These include vCJD, hepatitis E virus, dengue viruses, chikungunya virus, *Babesia* spp., West Nile virus and Middle East respiratory syndrome coronavirus -- although the list of potential threats includes approximately 70 such agents [49](#vox12367-bib-0049){ref-type="ref"}. For example, in the USA, transfusion‐transmitted babesiosis has been documented in more than 200 instances and is associated with the greatest case fatality rate of transfusion‐related infections [50](#vox12367-bib-0050){ref-type="ref"}.

Haemovigilance for transfusion‐transmitted infection is meant to capture pathogen transmission from donor to recipient. The requirements include the demonstration of the pathogen in the transfused component, or in the donor at the time of donation, or in an additional component from the same donation, or in an additional recipient of a component from the same donation [48](#vox12367-bib-0048){ref-type="ref"}. Also required is documentation that there are no other potential exposures to the pathogen that could be identified in the recipient and either evidence that the recipient was not infected with the pathogen prior to transfusion or evidence that the pathogen strains are related by molecular or extended phenotypic comparison testing [48](#vox12367-bib-0048){ref-type="ref"}. This is a difficult target to reach when such in‐depth testing is not usually conducted with each transfusion. Therefore, the pooled rate of transfusion‐transmitted bacterial sepsis was very low (0·83/1 million RBC units). There are few published reports of prospective surveillance for comparison purposes. Barrett and colleagues[51](#vox12367-bib-0051){ref-type="ref"} found a bacterial contamination rate of 3·2/100 000 RBC units, while Dzieczkowski and colleagues[37](#vox12367-bib-0037){ref-type="ref"} reported this rate to be 14·1/100 000 RBC units. In a more recent report from Denmark, 35% of RBC units contained viable bacteria which were obtained from donors 50 years of age or older [52](#vox12367-bib-0052){ref-type="ref"}.

There are avenues for improvement in existing haemovigilance systems. The addition of active surveillance components may enhance reporting. Expansion of electronic medical records to incorporate more information regarding blood administration may augment comprehensiveness. Adjunct programming routines could be enacted to capture pre‐ and post‐transfusion temperatures so that detection of FNHTR could be improved. Likewise, electronic capture of pre‐ and post‐transfusion blood pressures could assist the detection of hypotensive reactions. Some have already merged records from transfusion and apheresis medicine with the main electronic medical record [53](#vox12367-bib-0053){ref-type="ref"}, [54](#vox12367-bib-0054){ref-type="ref"}, [55](#vox12367-bib-0055){ref-type="ref"}. The SCANDAT2 is a successful example of linked donor and recipient health information in Sweden and Denmark [55](#vox12367-bib-0055){ref-type="ref"}. In addition, international networks (e.g. International Haemovigilance Network [56](#vox12367-bib-0056){ref-type="ref"}, Global Vigilance and Surveillance Database for Medical Products of Human Origin [57](#vox12367-bib-0057){ref-type="ref"}, World Health Organization Global Database on Blood Safety[58](#vox12367-bib-0058){ref-type="ref"}) provide opportunities for surveillance and the improvement of blood safety.

National haemovigilance programmes afford an important aspect of patient safety. Such systems generally capture serious transfusion reactions but, with improvement, could generate more comprehensive information. Cross‐country comparisons can provide the basis for discovery and continuous process improvement.
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